- Issuer ticker
-
PBYI
- Reported as of
-
06 Jul 2026
- Net transaction value
-
-$77,557
- SEC form
-
4
- Accepted by SEC
-
08 Jul 2026, 20:18:34 UTC
Filing notes and source
Key filing fact
Maximo F. Nougues filed Form 4 for PUMA BIOTECHNOLOGY, INC. (PBYI) on 08 Jul 2026.
Key facts
- This page summarizes Maximo F. Nougues's Form 4 filing for PUMA BIOTECHNOLOGY, INC. (PBYI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 Jul 2026, 20:18.
Change
- Previous filing in this sequence was filed on 20 Feb 2026.
- Current net transaction value: -$77,557.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0001758507
Primary reporting owner
NOUGUES MAXIMO F
- Relationship
-
Chief Financial Officer
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PBYI
transaction
Common Stock
Sale
- Transaction value
- -$77,557
- Shares
- -9,386
- Change %
- -3.9%
- Price
-
$8.26
- Shares after
- 230,637
- Date
- 06 Jul 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses
1 footnote